PGI13 DIRECT ECONOMIC BURDEN OF CHRONIC HEPATITIS C VIRUS IN A LARGE MANAGED CARE POPULATION  by Davis, KL et al.
Between group comparisons (before, after, and change) were all
non-signiﬁcant except for Rx drugs ($19 higher for IBS+C,
P < 0.05) and other ($8 higher for C, P < 0.05) in the after period
as well as the change for Rx drugs ($16 higher for IBS+C,
P < 0.05). Within groups, costs for Rx Drugs signiﬁcantly
increased in both cohorts and outpatient and ED signiﬁcantly
increased for the C cohort. CONCLUSION: Patients with con-
stipation and IBS+C incur similar costs throughout the health
care system.
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OBJECTIVE: To estimate differences in health care costs
between Crohn’s disease (CD) patients and controls and to
examine differences in CD costs by prescription therapy.
METHODS: Administrative claims data from geographically
diverse private US health plans with service dates between
January 1, 2002 and December 31, 2005 were utilized. CD
patients (ICD-9-CM code 555.x) were identiﬁed and matched to
controls in a 1:5 ratio on age, gender, health plan, and duration
of enrollment. Two part models (logistic regression for likelihood
to incur any costs and log-transformed regression for costs) were
used to estimate costs (amounts paid by health plans for medical
services and pharmaceuticals), controlling for socio-demographic
characteristics and medical co-morbidities. CD patients were
grouped by drug regimen as follows: steroids, immunosuppres-
sants, inﬂiximab, any combination of the three drug classes, and
no regimen or regimens not including the three studied drug
classes. Average per patient per day medical and pharmaceutical
cost was estimated for each group and projected annually.
RESULTS: A total of 9,302 CD patients and 46,510 matched
controls were identiﬁed. The mean age in each group was 46.9
and 55.8% were females. Annual total predicted costs per patient
were over 3 times higher in the CD group ($11,569) than the
control group ($3,564, p < 0.01). Medical and pharmacy costs
were the lowest in the group receiving no regimen/regimens not
including studied classes. Medical costs were at least 50% higher
in patients receiving combination therapy that included steroids
than those receiving combinations not including steroids. CON-
CLUSION: CD patients incur signiﬁcantly greater costs than
matched controls. CD patients on no regimen/regimens not
studied incur few costs suggesting that they may be experiencing
remission or mild symptoms. Steroids are associated with signiﬁ-
cantly higher medical costs, which may be suggestive of uncon-
trolled symptoms or ﬂares requiring medical resources.
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OBJECTIVE: Hepatitis C virus (HCV) is one of the most
common blood-borne infections in the US. The cost burden of
HCV to third party payers has not been widely investigated using
administrative data. We analyzed retrospective insurance claims
to estimate total, all-cause resource utilization and costs among
managed care enrollees with chronic HCV compared to similar
subjects without HCV. METHODS: A large US claims database
was analyzed from January 1, 2002 through December 31, 2006.
Inclusion criteria were: 1 diagnosis of chronic HCV (ICD-9
070.44, 070.54, 070.70, or 070.71); no evidence of hepatitis B;
12 months of continuous plan enrollment post-diagnosis. Per
patient use and costs of all medical services and prescription
drugs utilized over a 12-month period post-diagnosis were evalu-
ated. Outcomes were also assessed in controls without HCV
matched (1:1) on age, gender, and length of plan enrollment.
RESULTS: A total of 20,662 patients met all inclusion criteria.
Mean age was 49 years and 61% were male. Total costs were
$20,830 per HCV patient, compared to $4673 per control
(P < 0.0001). Hospitalization was seen in 24% of HCV patients
compared to 7% of controls (P < 0.0001), with mean inpatient
costs of $5765 and $1031 per patient, respectively (P < 0.0001).
Patients with HCV had signiﬁcantly higher (P < 0.0001) pre-
scription costs compared to controls ($6178 vs. $1097), as well
as increased use and costs of other medical services, including
ofﬁce visits (23 vs. 11 visits; $2112 vs. $1036), other ancillary
services ($4800 vs. $1301), emergency care (32% vs. 14% with
1 admission; $387 vs. $114), and laboratory tests ($741 vs.
$110). CONCLUSION: Costs incurred by payers for patients
with HCV are more than four times the costs attributable to
individuals without HCV. Pharmacy and inpatient services are
drivers of these costs. Health plans should be aware of height-
ened costs for enrollees with HCV when considering formulary
access for treatments.
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OBJECTIVE: Studies have shown that continuous and
on-demand use of proton pump inhibitors (PPI) are more efﬁca-
cious and cost-effective strategies than continuous histamine-2
receptor antagonist (H2RA) use for maintenance therapy of gas-
troesophageal reﬂux disease (GERD). Recent research has raised
questions about potential safety concerns of hip fractures and
acute myocardial infarction (AMI) associated with long-term PPI
use. This study integrates treatment efﬁcacy with emerging safety
data to compare the cost-effectiveness from the payer perspective
of continuous PPI use, on-demand PPI use, and continuous
H2RA use for maintenance therapy for GERD. METHODS: A
Markov model was designed to simulate, over ﬁve years, the
clinical and economic outcomes of GERD patients asymptomatic
after initial acute treatment on maintenance therapy with PPIs or
H2RA. The transition probabilities, costs, and utilities were
derived from the peer-reviewed literature. Sensitivity analysis was
conducted to examine the robustness of the model and to deter-
mine the thresholds at which safety issues may alter therapeutic
decisions. RESULTS: In the base-case efﬁcacy model, intermit-
tent PPI treatment was the least costly and least effective strategy,
whereas the step-down PPI strategy was most costly and most
effective, with an incremental cost-effectiveness ratio (ICER) of
$24,636 per quality-adjusted life-year (QALY), relative to the
intermittent PPI strategy. The maintenance H2RA strategy was
dominated throughout the sensitivity analysis. The results were
consistent when hip fracture events were introduced into the
model, with the step-down PPI strategy ICER increasing to
$29,113/QALY. Threshold analysis for AMI showed the hypoth-
esized relative risk (RR) would need to be 11.9 before mainte-
nance H2RA therapy would be considered a cost-effective
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